These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 11139961

  • 1. Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia.
    Boriani G, Biffi M, De Simone N, Bacchi L, Martignani C, Bitonti F, Zannoli R, Butrous G, Branzi A.
    Pacing Clin Electrophysiol; 2000 Nov; 23(11 Pt 2):1935-8. PubMed ID: 11139961
    [Abstract] [Full Text] [Related]

  • 2. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, Brachmann J, Biffi M, Butrous GS, Ventricular Arrhythmias Dofetilide Investigators.
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [Abstract] [Full Text] [Related]

  • 3. Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation.
    Sauer AJ, Kaplan R, Xue J, Dorsey P, Hayes M, Shah SJ, Passman R.
    Am J Cardiol; 2014 Jun 15; 113(12):2030-5. PubMed ID: 24793679
    [Abstract] [Full Text] [Related]

  • 4. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
    McBride BF, Min B, Kluger J, Guertin D, Henyan NN, Coleman CI, Silver BB, White CM.
    Ann Noninvasive Electrocardiol; 2006 Apr 15; 11(2):163-9. PubMed ID: 16630091
    [Abstract] [Full Text] [Related]

  • 5. Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
    Ting C, Malloy R, Knowles D.
    J Cardiovasc Pharmacol Ther; 2020 Sep 15; 25(5):438-443. PubMed ID: 32347108
    [Abstract] [Full Text] [Related]

  • 6. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML, Rasmussen HS, Cobbe SM.
    Am J Cardiol; 1992 Dec 01; 70(18):1432-7. PubMed ID: 1442614
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
    Parkash R, Nault I, Rivard L, Gula L, Essebag V, Nery P, Tung S, Raymond JM, Sterns L, Doucette S, Wells G, Tang ASL, Stevenson WG, Sapp JL.
    Circ Arrhythm Electrophysiol; 2018 Jan 01; 11(1):e005663. PubMed ID: 29305400
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.
    Allen MJ, Oliver SD, Newgreen MW, Nichols DJ.
    Br J Clin Pharmacol; 2002 Jan 01; 53(1):59-65. PubMed ID: 11849196
    [Abstract] [Full Text] [Related]

  • 11. [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy].
    Sarubbi B, Ducceschi V, Briglia N, Esposito R, Mayer MS, Scialdone A, Santangelo L, Iacono A.
    Cardiologia; 1996 Jul 01; 41(7):645-51. PubMed ID: 8983831
    [Abstract] [Full Text] [Related]

  • 12. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
    Hoffmann E, Mattke S, Haberl R, Steinbeck G.
    J Cardiovasc Pharmacol; 1993 Jan 01; 21(1):95-100. PubMed ID: 7678686
    [Abstract] [Full Text] [Related]

  • 13. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide.
    Brendorp B, Elming H, Jun L, Køber L, Torp-Pedersen C, Diamond Study Group.
    Clin Cardiol; 2003 May 01; 26(5):219-25. PubMed ID: 12769249
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.
    Boriani G, Biffi M, Bacchi L, Martignani C, Zannoli R, Butrous GS, Branzi A.
    Eur J Clin Pharmacol; 2002 Jun 01; 58(3):165-9. PubMed ID: 12107600
    [Abstract] [Full Text] [Related]

  • 16. Reduction in QT dispersion by sotalol following myocardial infarction.
    Day CP, McComb JM, Matthews J, Campbell RW.
    Eur Heart J; 1991 Mar 01; 12(3):423-7. PubMed ID: 2040324
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dynamic analysis of dofetilide-induced changes in ventricular repolarization.
    Lande G, Maison-Blanche P, Fayn J, Ghadanfar M, Coumel P, Funck-Brentano C.
    Clin Pharmacol Ther; 1998 Sep 01; 64(3):312-21. PubMed ID: 9757155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.